

Special Issue

DNA Repair Targeted Therapy: New Advances in Cancer Treatment

Message from the Guest Editor

Cancer treatment has seen a revolutionary shift with the recognition of DNA repair mechanisms in tumor cells. Over time, understanding how these repair processes safeguard cancer cells from traditional therapies has become a focal point for improving treatment efficacy. The aim of this Special Issue is to showcase the latest breakthroughs in DNA repair-targeted cancer therapy. It will cover research on novel molecular targets involved in DNA repair pathways, the development of drugs that specifically disrupt these pathways, and the evaluation of combination therapies with existing cancer treatments. Cutting-edge research in this field includes the utilization of gene-editing technologies like CRISPR-Cas systems to manipulate DNA repair genes in cancer cells. Additionally, the exploration of immune-based therapies in combination with DNA repair inhibitors, leveraging the body's immune system to enhance the effects of targeting DNA repair processes. We are interested in original research articles, in-depth reviews, and case reports that present new findings on DNA repair-targeted therapies.

Guest Editor

Dr. Nimrat Chatterjee

Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA

Deadline for manuscript submissions

31 October 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/261214

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)